Brian Park, PharmD, Author at Infectious Disease Advisor
Brian Park, PharmD

Brian Park, PharmD

Drug Information Specialist https://www.infectiousdiseaseadvisor.com
Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

vaccine

BCG Vaccination and Cancer Risk: What’s the Link?

Bacillus Calmette Guérin (BCG) vaccination in childhood was associated with a reduced risk of lung cancer development in American Indian and Alaska Native (AI/AN) populations, according to findings from a 60-year follow-up of a clinical trial.  The review analyzed a multicenter, randomized by alternation, placebo-controlled, single-blind clinical trial that was conducted from December 1935 to…

Investigational Vaccine to Prevent RSV in Older Patients Gets Breakthrough Status

Janssen announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for their investigational prophylactic vaccine for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in adults aged 60 years and older. RSV is a highly prevalent and contagious respiratory infection. It is the most common cause of bronchitis…

FDA Approves First-In-Class Antibiotic to Treat Community-Acquired Bacterial Pneumonia

The FDA has approved Xenleta (lefamulin; Nabriva Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.

Next post in Antibiotics, Antimicrobial Resistance